Navigation Links
BioSante Pharmaceuticals Announces New Findings for Potential Bird,Flu Vaccine

of bird flu. At the start of the trial, mice received either the H5N1 antigen alone or in a formulation with BioVant. A booster immunization was administered after two weeks. Results indicated that the administration of a BioVant-H5N1 formulation stimulated production of high titers of H5N1-specific antibodies, which were significantly higher than H5N1 alone. Anti-avian flu antibody levels continued to increase over the entire study period, suggesting good duration of immunity.

Avian flu refers to a large group of different influenza viruses that primarily affect birds. While the vast majority of these viruses do not affect humans, the H5N1 strain already has made the jump from birds to humans and in fact, has infected 310 people and killed 190 since the outbreak of the disease in 2003, and more than 250 million chickens have been killed to stop the spread of the virus. Farmers and poultry producers already have suffered losses in the billions of dollars. There is widespread concern that a strain of avian flu will mutate into a new form that is contagious among humans. Since there is currently no truly effective vaccine available to protect humans from H5N1 and humans do not have antibodies to fight this new virus strain, there is significant risk of a pandemic.

An adjuvant is a substance that, when added to a vaccine, enhances the vaccine's effectiveness by stimulating an immune system response. In multiple studies, BioVant has been shown to be safe and cause minimal dose-dependent inflammation at the injection site, and has been shown to both prevent the manifestation of allergic response, and, to effectively 'switch off' established Th2-T-cell-associated allergic disease.

About BioSante Pharmaceuticals, Inc.

BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. B
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
3. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
4. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
5. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
6. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:8/3/2015)... 3, 2015  CytomX, a biopharmaceutical company developing ... announced the promotion of several members of its ... who previously served as vice president of business ... senior vice president of corporate development and strategy. ... as the vice president of business development at ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... 3, 2015  Encision Inc. (PK:ECIA), a medical device ... electrosurgical burns in minimally invasive surgery, today announced financial ... June 30, 2015. The Company posted quarterly ... loss of $213 thousand, or $(0.02) per share. These ... a net loss of $202 thousand, or $(0.02) per ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... NEW YORK, Feb. 2, 2011 Reportlinker.com announces that ... catalogue: US Prebiotics Industry ... report analyzes the US And European markets for Prebiotics ... is further analyzed by the following product segments: Mannan-Oligosaccharide ...
... Feb. 2, 2011 H. D. Smith recently announced ... strategic planning and business development, Robert Appleby to corporate ... vice president marketing.  These appointments are the latest organizational ... address evolving customer needs. Joseph ...
Cached Medicine Technology:US Prebiotics Industry 2US Prebiotics Industry 3US Prebiotics Industry 4US Prebiotics Industry 5US Prebiotics Industry 6US Prebiotics Industry 7H. D. Smith Aligns Leadership Positions to Fill Three Senior Roles 2
(Date:8/4/2015)... ... 04, 2015 , ... In the most recent talcum powder ... report that a new location for pretrial proceedings is under consideration, according to ... warning information at their website, the Talcum Powder Cancer Lawsuit Center. , The ...
(Date:8/4/2015)... ... August 04, 2015 , ... IN AMERICA ... which spotlights treating depression. Depression affects millions of Americans every single year. To ... inform and enlighten viewers with the latest segment produced with the assistance of ...
(Date:8/3/2015)... , ... August 04, 2015 , ... ... Armethia Holt as a 2015-2016 inductee into the NAPW VIP Woman of ... healthcare. With more than 700,000 members and over 200 operating Local Chapters, NAPW ...
(Date:8/3/2015)... ... ... offers the most affordable web design and SEO services for start up companies. Every ... dollar. Every company that is starting out needs to be online in this technology ... a start up need to be online, they need to physically be present and visible ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Since 1978, the ... declined, according to a new publication released today by the AAMC (Association of American ... college graduates over the past three decades, the number of black male applicants to ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:National Association of Professional Women Inducts Armethia Holt, CEO at AA&G Group Homes, LLC, Into its VIP Woman of the Year Circle 2Health News:Web SEO Master, a division of SH Web Design & SH Web Commerce, Inc. begins offering Web Design and SEO Services for Start Up Companies located in Indianapolis, Indiana 2Health News:Web SEO Master, a division of SH Web Design & SH Web Commerce, Inc. begins offering Web Design and SEO Services for Start Up Companies located in Indianapolis, Indiana 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4
... In a follow-up study, researchers at Moffitt Cancer Center and ... cancer might experience prolonged fatigue years after their therapy. The ... of CANCER , is a follow-up to a study ... researchers published in CANCER in 2007. "Fatigue ...
... , MONDAY, Dec. 5 (HealthDay News) --,Hospitalized patients ... most common cause of infectious diarrhea in hospitals -- will ... new study indicates. Experts say prevention is key to ... C. difficile . For the study, published Dec. 5 ...
... News) -- Teenagers with autism who also have epilepsy ... The combination means that certain behaviors common among ... front of their faces -- could increase their risk ... to 14 percent of children with epilepsy, the rate ...
... By Alan Mozes HealthDay Reporter , SUNDAY, Dec. ... to face an increased risk for seizures while watching 3-D ... did reveal that about one in five of these children ... including nausea, headaches and dizziness. "Normal people have a ...
... University of New Hampshire Crimes against Children Research Center suggest ... found the percentage of youth who send nude pictures of ... The other found that when teen sexting images do come ... like sex offenders. The studies were carried out by ...
... Barcelona, 1st December, 2011.- A study by researchers Ral ... in Biomedicine (IRB Barcelona) and Pilar Navarro at the ... a new reprogramming mechanism for the expression of genes ... cell. In the study, published in this week,s edition ...
Cached Medicine News:Health News:Follow-up study finds prolonged fatigue for those who had chemotherapy for breast cancer 2Health News:Common Hospital Infection Lengthens Patient Stays 2Health News:3-D TV Doesn't Raise Seizure Risk for Kids With Epilepsy: Study 2Health News:3-D TV Doesn't Raise Seizure Risk for Kids With Epilepsy: Study 3Health News:Concerns about teen sexting overblown, according to new UNH research 2Health News:Discovery of a new reprogramming mechanism for tumor cells 2
Designed to give maximum drying area while taking up minimal bench space....
Used to remove wrinkles from sections and for reorientating embedded tissue....
Compact instrument that quickly dries racks of slides using warm air....
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Medicine Products: